{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Biora Therapeutics, Inc.
Is Biora Therapeutics, Inc. overvalued or undervalued?
As of August 15, 2022, Biora Therapeutics, Inc. is considered overvalued and has a concerning investment outlook due to its extreme EV to Sales ratio of 36.76, negative financial metrics, and significant underperformance compared to the S&P 500.
Is Biora Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2023, there is insufficient technical data for Biora Therapeutics, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Biora Therapeutics, Inc.?
As of March 2022, Biora Therapeutics, Inc.'s management team includes Dr. Harry Stylli as Chairman and CEO, along with independent directors Mr. Jeffrey Alter, Mr. John Bigalke, Mr. Jeffrey Ferrell, Dr. Brian Kotzin, and Dr. Samuel Nussbaum.
What does Biora Therapeutics, Inc. do?
Biora Therapeutics, Inc. is a biotechnology company focused on developing molecular testing products and precision medicine. As of September 2024, it has a market cap of $0.75 million, with net sales of $0 million and a net loss of $22 million.
How big is Biora Therapeutics, Inc.?
As of Jun 18, Biora Therapeutics, Inc. has a market capitalization of 0.75 million, with net sales of 0.89 million and a net profit of -35.58 million over the last four quarters. As of Dec 23, the company reported shareholder's funds of -101.42 million and total assets of 31.21 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
